The Clinical Effects of Laser Acupuncture on Hospitalized Patients With Severe COVID-19: A Randomized Clinical Trial

被引:0
|
作者
Shojaeddin, Arista [1 ]
Fatemi, Alireza [2 ]
Razzaghi, Zahra [1 ]
Pishgahi, Mehdi [3 ]
Sherafat, Somayeh Jahani [1 ]
Razzaghi, Mohammadreza [1 ]
Shahrzad, Mohamad Karim [4 ]
Anaraki, Nafiseh [4 ]
Salehi, Chiman [4 ]
Amiri, Aslan [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Cardiol Dept, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Internal Med & Endocrinol Dept, Tehran, Iran
关键词
Laser acupuncture; Laser therapy; COVID-19; Severity; THERAPY LLLT; PAIN; IRRADIATION; IL-1-BETA; RELEVANCE; ASTHMA; BLIND; LUNG; ACTS;
D O I
10.34172/jlms.2023.14
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The coronavirus disease (COVID-19) was extended to the entire population in China and around the world, and its mortality rate was about 3.4%. The impact of laser therapy on chronic respiratory diseases has been shown in previous studies. This study was aimed at examining the effects of laser acupuncture (LA) on patients with severe COVID-19. Methods: In the present study, 60 patients with a positive reverse transcription-polymerase chain reaction (RT-PCR) test were assigned to the intervention and control groups (30 patients in each group). The intervention group was treated with LA, that is, laser light with low energy on acupuncture points, once a day for five consecutive days. Results: The participants' mean age in the intervention and control groups was 48.96 +/- 12.65 and 53.16 +/- 12.28 respectively; 70% of the patients were male and 30% of them were female. IL6 had a significant reduction in the intervention group (P value = 0.038) in comparison with the control group (P value = 0.535). Furthermore, the mean admission time in the control group was significantly higher than that in the intervention group (P value = 0.047). However, the mortality rate in the intervention group was zero, but three patients in the control group died. Conclusion: Our study showed that LA can be used as supportive therapy for routine treatment in patients with severe COVID-19. Moreover, due to LA safety and it's low cost, it could be recommended as an adjuvant to conventional therapy in patients interested in treating their disease with such a method.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial
    Saeedi-Boroujeni, Ali
    Nashibi, Roohangiz
    Ghadiri, Ata A.
    Nakajima, Motowo
    Salmanzadeh, Shokrollah
    Mahmoudian-Sani, Mohammad-Reza
    Hanafi, Mohammad Ghasem
    Sharhani, Asaad
    Khodadadi, Ali
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (04) : 368 - 377
  • [22] A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
    Abuhasira, Ran
    Ayalon-Dangur, Irit
    Zaslavsky, Neta
    Koren, Ronit
    Keller, Mally
    Dicker, Dror
    Grossman, Alon
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [23] COVIDMED-An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients
    Freilich, Daniel
    Victory, Jennifer
    Jenkins, Paul
    Gadomski, Anne
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2022, 29
  • [24] Intranasal Versus Intravenous Dexamethasone to Treat Hospitalized COVID-19 Patients: A Randomized Multicenter Clinical Trial
    Cardenas, Graciela
    Chavez-Canales, Maria
    Espinosa, Ana Maria
    Jordan-Rios, Antonio
    Malagon, Daniel Anica
    Murillo, Manlio Fabio Marquez
    Araujo, Laura Victoria Torres
    Campos, Ricardo Leopoldo Barajas
    Wong-Chew, Rosa Maria
    Gonzalez, Luis Esteban Ramirez
    Cresencio, Karent Ibet
    Velazquez, Enrique Garcia
    de la Cerda, Mariana Rodriguez
    Leyva, Yoana
    Hernandez-Ruiz, Joselin
    Hernandez-Medel, Maria Luisa
    Leon-Hernandez, Mireya
    Quero, Karen Medina
    Moncivais, Anahi Sanchez
    Sarmiento, Eduardo Beltran
    Reynoso, Rafael Ignacio Aguilar
    Reyes, Daniela Murillo
    Ambriz, Luis Rodrigo del Rio
    Hernandez, Juan Salvador Garcia
    Cruz, Jocelyn
    Ferrer, Sergio Ivan Valdes
    Huerta, Leonor
    Fierro, Nora Alma
    Hernandez, Marisela
    Perez-Tapia, Mayra
    Meneses, Gabriela
    Rosas, Gabriela
    Hernandez-Aceves, Juan Alberto
    Cervantes-Torres, Jaquelynne
    Valdez, Ricardo A.
    Rodriguez, Anai Fuentes
    Espindola-Arriaga, Erick
    Ortiz, Mauricio
    Salazar, Evelyn Alvarez
    Barba, Carlos Castellanos
    Besedovsky, Hugo
    Romano, Marta C.
    Jung, Helgi
    Bobes, Raul J.
    Soldevila, Gloria
    Lopez-Alvarenga, Juan C.
    Fragoso, Gladis
    Laclette, Juan Pedro
    Sciuttoi, Edda
    ARCHIVES OF MEDICAL RESEARCH, 2024, 55 (02)
  • [25] Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial
    Morales-Ortega, Alejandro
    Farfan-Sedano, Ana Isabel
    San Martin-Lopez, Juan Victor
    Escriba-Barcena, Almudena
    Jaenes-Barrios, Beatriz
    Madronal-Cerezo, Elena
    Llarena-Barroso, Cristina
    Mesa-Plaza, Nieves
    Frutos-Perez, Begona
    Ruiz-Giardin, Jose Manuel
    Duarte-Millan, Miguel Angel
    Piedrabuena-Garcia, Sara Isabel
    Carpintero-Garcia, Lorena
    Canalejo-Castrillero, Eduardo
    Mora-Hernandez, Belen
    Garcia-Parra, Carlos Javier
    Magro-Garcia, Hector Agustin
    Algaba-Garcia, Alicia
    Hernandez-Muniesa, Belen
    Nasarre-Lopez, Berta
    Ontanon-Nasarre, Ana
    Dominguez-Garcia, Maria Jesus
    Gomez-Santos, Dulce
    Prieto-Menchero, Santiago
    Garcia de Tena, Jaime
    Bermejo, Fernando
    Garcia-Gil, Mario
    Gonzalo-Pascua, Sonia
    Bernal-Bello, David
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [26] Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial
    Azizi, Hanieh
    Rouhani, Nima
    Shaki, Fatemeh
    Karimpour-razkenari, Elahe
    Ghazaeian, Monireh
    Salehifar, Ebrahim
    Saeedi, Majid
    Fallah, Sahar
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [27] Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial
    Dastenae, Zahra Habibi
    Bahadori, Azadeh
    Dehghani, Marziyeh
    Asadi-Samani, Majid
    Izadi, Iman
    Shahraki, Hadi Raeisi
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 659 - 664
  • [28] Effect of parenteral L-carnitine in hospitalized patients with moderate to severe COVID-19: A randomized double-blind clinical trial
    Naeimzadeh, Farnaz
    Sadeghi, Armin
    Saghaleini, Seiedhadi
    Sarbakhsh, Parvin
    Mahmoodpoor, Ata
    Gharekhani, Afshin
    BIOIMPACTS, 2024,
  • [29] Effects of hypokalemia on clinical outcomes in hospitalized patients with Covid-19 pneumonia
    Kaya, Bulent
    Paydas, Saime
    Kuzu, Tolga
    Demiroglu, Omer
    Yucel, Sevinc Puren
    Balal, Mustafa
    Tasova, Yesim
    CUKUROVA MEDICAL JOURNAL, 2021, 46 (04): : 1650 - 1656
  • [30] Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
    Ansarin, Khalil
    Tolouian, Ramin
    Ardalan, Mohammadreza
    Taghizadieh, Ali
    Varshochi, Mojtaba
    Teimouri, Soheil
    Vaezi, Tahere
    Valizadeh, Hamed
    Saleh, Parviz
    Safiri, Saeid
    Chapman, Kenneth R.
    BIOIMPACTS, 2020, 10 (04) : 209 - 215